Sunday, November 14, 2004

Drug Licensed for Pathological Gambling

Somaxon and BioTie in pathological gambling licensing deal

The North American market is soon going to see the introduction of a drug specifically designed for pathological gamblers. Apparantly, this market is underdeveloped with no specific drug therapy currently approved or available.

The company Somaxon Pharmaceuticals have agreed a multi-million dollar licensing deal with Biotie Therapies to develop Nalmefene with phase III clinical trials to begin in 2005. The drug is marketed predominantly for impulse control disorders and alcohol abuse.

Personally speaking, there is always something unsettling about the use of drugs for psychological disorders such as gambling addiction. Thankfully there are a number of support groups available for problem gamblers that are already established such as Gamblers Anonymous

Gamblers Anonymous


Post a Comment

<< Home